Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

First-episode schizophrenia: Antipsychotics tied to metabolic abnormalities early in treatment

Key clinical point: Treatment with antipsychotic medication may be significantly associated with insulin resistance and lipid metabolic abnormalities as early as 2 weeks after the initiation.

Major finding: After 2 weeks, treatment with antipsychotics was significantly associated with elevated levels of triglycerides, total cholesterol, and low-density lipoprotein cholesterol (P less than .05 for all). Fasting glucose and high-density lipoprotein cholesterol levels decreased significantly after 2 and 4 weeks of antipsychotic treatment, respectively (P less than .05 for both). Antipsychotic treatment was associated with a statistically significant overall increase in the levels of insulin resistance after 4 weeks (P less than .05).

Study details: The data come from a retrospective real-world study involving 853 first-episode drug-naïve and 472 first-episode medicated patients with schizophrenia.

Disclosures: The study was partly funded by the National Nature Science Foundation of China; the National Key R & D Program; the Ministry of Science and Technology, China; the Department of Science and Technology of Sichuan provincial government; and the West China Hospital of Sichuan University. The authors declared no conflicts of interest.

Citation:

Cao H et al. J Psychiatr Res. 2020 August 10. doi: 10.1016/j.jpsychires.2020.07.038.